Bernd Seizinger
Director/Board Member bei APTOSE BIOSCIENCES INC.
Vermögen: 2 Mio $ am 30.04.2024
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Christian Schade | M | 63 |
Aprea Therapeutics AB
 Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | 8 Jahre |
| William Rice | M | 65 | 11 Jahre | |
| Thomas Meier | M | 62 | 20 Jahre | |
| Scott Rocklage | M | 69 |
Aprea Therapeutics AB
Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | 8 Jahre |
| Leonard Kruimer | M | 66 | 8 Jahre | |
| Matthew Coffey | M | - | 13 Jahre | |
| Agnete Brunsvik Fredriksen | M | 47 | 17 Jahre | |
| Björn Frendéus | M | 51 | 23 Jahre | |
| John Hamill | M | 60 | 1 Jahre | |
| John Henneman | M | 62 |
Aprea Therapeutics AB
Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | 5 Jahre |
| Oren Gilad | M | 56 | 2 Jahre | |
| Richard Peters | M | 61 | 4 Jahre | |
| Wayne Pisano | M | 69 | 11 Jahre | |
| Martin Welschof | M | 63 | 6 Jahre | |
| Christian Rohlff | M | 62 |
Oxford BioTherapeutics Ltd.
 Oxford BioTherapeutics Ltd. Pharmaceuticals: MajorHealth Technology Oxford BioTherapeutics Ltd. develops antibody-based medicines for oncology. The firm offers antibody-based cancer drugs with integrated diagnostics against novel targets. The company was founded by Christian Rohlff in 2003 and is headquartered in Abingdon, the United Kingdom. | 21 Jahre |
| Gabriela Gruia | M | 67 | 1 Jahre | |
| Michael Engsig | M | - | 17 Jahre | |
| Warren Whitehead | M | 71 | 13 Jahre | |
| Anne Michelle Whitaker | F | 56 | - | |
| Anna Martling | M | 55 |
Karolinska Institutet
| - |
| Deborah Brown | F | - | 7 Jahre | |
| Kristof Zsolt Szalay | M | 38 |
Turbine Simulated Cell Technologies Ltd.
 Turbine Simulated Cell Technologies Ltd. Information Technology ServicesTechnology Services Turbine Simulated Cell Technologies Ltd. is a British company that leverages AI technology to understand oncology patients with simulated cells. The company is based in London, UK. and has subsidiaries in Hungary. The company was founded in 2019 by Szabolcs Nagy, Ivan Fekete, Daniel Veres, Kristof Zsolt Szalay. Szabolcs Nagy has been the CEO since 2019. | - |
| Kristoffer Bissessar | M | 56 | 6 Jahre | |
| Lars Wegner | M | 50 |
Turbine Simulated Cell Technologies Ltd.
Turbine Simulated Cell Technologies Ltd. Information Technology ServicesTechnology Services Turbine Simulated Cell Technologies Ltd. is a British company that leverages AI technology to understand oncology patients with simulated cells. The company is based in London, UK. and has subsidiaries in Hungary. The company was founded in 2019 by Szabolcs Nagy, Ivan Fekete, Daniel Veres, Kristof Zsolt Szalay. Szabolcs Nagy has been the CEO since 2019. | 1 Jahre |
| Rakesh Kumar Jain | M | 74 |
The General Hospital Corp.
 The General Hospital Corp. Hospital/Nursing ManagementHealth Services The General Hospital Corp. provides healthcare services. It offers diagnostic and therapeutic are in every specialty and subspecialty of medicine and surgery. The firm's care center provides cancer, digestive disorders, heart disease, transplantation and vascular medicine services. The company was founded in 1811 and is headquartered in Boston, MA.
Harvard Medical School
| 33 Jahre |
| Michael Grissinger | M | 70 | 2 Jahre | |
| Carol Ashe | F | 66 | 6 Jahre | |
| Jean Bizzari | M | 69 |
Oxford BioTherapeutics Ltd.
Oxford BioTherapeutics Ltd. Pharmaceuticals: MajorHealth Technology Oxford BioTherapeutics Ltd. develops antibody-based medicines for oncology. The firm offers antibody-based cancer drugs with integrated diagnostics against novel targets. The company was founded by Christian Rohlff in 2003 and is headquartered in Abingdon, the United Kingdom. | 1 Jahre |
| Anders Tuv | M | 46 | - | |
| Marc Duey | M | 68 | 2 Jahre | |
| Angela Holtham | F | 73 | 10 Jahre | |
| Klas Kärre | M | 70 |
Karolinska Institutet
| - |
| Denis Burger | M | 80 | 17 Jahre | |
| Peter Sjöstrand | M | 78 |
Karolinska Institutet
| - |
| Jane Rhodes | M | 56 |
Turbine Simulated Cell Technologies Ltd.
Turbine Simulated Cell Technologies Ltd. Information Technology ServicesTechnology Services Turbine Simulated Cell Technologies Ltd. is a British company that leverages AI technology to understand oncology patients with simulated cells. The company is based in London, UK. and has subsidiaries in Hungary. The company was founded in 2019 by Szabolcs Nagy, Ivan Fekete, Daniel Veres, Kristof Zsolt Szalay. Szabolcs Nagy has been the CEO since 2019. | 1 Jahre |
| Rifat Pamukcu | M | 66 | 2 Jahre | |
| Mark Vincent | M | 71 | 17 Jahre | |
| Erich Maximilian Platzer | M | 74 | 10 Jahre | |
| Oliver Strub | M | 61 | 18 Jahre | |
| Cecilia Hofvander | F | - | 3 Jahre | |
| Stefan Ericsson | M | 61 | 26 Jahre | |
| Kirk Look | M | - | 21 Jahre | |
| Vincent Ossipow | M | 55 | 8 Jahre | |
| Hans Lennart Rudolf Wigzell | M | 86 |
Karolinska Institutet
| 29 Jahre |
| Daniel Veres | M | 35 |
Turbine Simulated Cell Technologies Ltd.
Turbine Simulated Cell Technologies Ltd. Information Technology ServicesTechnology Services Turbine Simulated Cell Technologies Ltd. is a British company that leverages AI technology to understand oncology patients with simulated cells. The company is based in London, UK. and has subsidiaries in Hungary. The company was founded in 2019 by Szabolcs Nagy, Ivan Fekete, Daniel Veres, Kristof Zsolt Szalay. Szabolcs Nagy has been the CEO since 2019. | - |
| Susan Pietropaolo | F | - | - | |
| Szabolcs Nagy | M | 35 |
Turbine Simulated Cell Technologies Ltd.
Turbine Simulated Cell Technologies Ltd. Information Technology ServicesTechnology Services Turbine Simulated Cell Technologies Ltd. is a British company that leverages AI technology to understand oncology patients with simulated cells. The company is based in London, UK. and has subsidiaries in Hungary. The company was founded in 2019 by Szabolcs Nagy, Ivan Fekete, Daniel Veres, Kristof Zsolt Szalay. Szabolcs Nagy has been the CEO since 2019. | - |
| Thomas Perlmann | M | - |
Karolinska Institutet
| - |
| Milind Kamkolkar | M | - |
Turbine Simulated Cell Technologies Ltd.
Turbine Simulated Cell Technologies Ltd. Information Technology ServicesTechnology Services Turbine Simulated Cell Technologies Ltd. is a British company that leverages AI technology to understand oncology patients with simulated cells. The company is based in London, UK. and has subsidiaries in Hungary. The company was founded in 2019 by Szabolcs Nagy, Ivan Fekete, Daniel Veres, Kristof Zsolt Szalay. Szabolcs Nagy has been the CEO since 2019. | 1 Jahre |
| Jeremy Skillington | M | 53 |
TriMod Therapeutics Ltd.
 TriMod Therapeutics Ltd. BiotechnologyHealth Technology TriMod Therapeutics Ltd develops novel platform technologies to treat cancer and autoimmune diseases. It offers TriMoVac technology that enhances the patients' immune response to the tumour and promotes its eradication by attenuating its' immune subversion strategies. The company was founded by Kingston Mills and Jeremy Skillingtonand in 2011 is headquartered in Dublin, Ireland. | 13 Jahre |
| Jan-Ingmar Flock | M | 75 |
Karolinska Institutet
| - |
| David H. Sachs | M | 77 |
Harvard Medical School
| 33 Jahre |
| Ronald Li | M | - |
Karolinska Institutet
| 8 Jahre |
| Michael C. Gibson | M | - |
Harvard Medical School
| 37 Jahre |
| Peter Sackey | M | 53 |
Karolinska Institutet
| - |
| Klaus Edvardsen | M | 62 | 2 Jahre | |
| Anders Gabrielsen | M | 58 |
Karolinska Institutet
| - |
| Rafael Bejar | M | 53 | 4 Jahre | |
| Karoline W. Schjetne | M | - | 7 Jahre | |
| Katrine Husum | F | - | 4 Jahre | |
| Caroline Ingre | M | 47 |
Karolinska Institutet
| - |
| Einar Jonsbru | M | - | - | |
| Emma Meurling | F | - | - | |
| Victor Montalvo-Lugo | M | - | 5 Jahre | |
| Gunvor Ester Ekman-Ordeberg | M | 80 |
Karolinska Institutet
| 23 Jahre |
| Kristoffer Rudenholm Hansson | M | 50 | 8 Jahre | |
| Kenneth R. Chien | M | - |
Karolinska Institutet
| - |
| Jerome Groopman | M | 72 |
Harvard Medical School
| 32 Jahre |
| Anders Vahlne | M | 78 |
Karolinska Institutet
| 30 Jahre |
| Rolf Lewensohn | M | - |
Karolinska Institutet
| - |
| Jan Haudemann-Andersen | M | - | - | |
| Erna Möller | F | - |
Karolinska Institutet
| - |
| George Demetri | M | 67 |
Harvard Medical School
| 36 Jahre |
| Carl Johan Bertil Sundberg | M | 66 |
Karolinska Institutet
| - |
| Gregory Verdine | M | 65 |
Harvard Medical School
| 35 Jahre |
| Rolf Valter Rikard Kiessling | M | 76 |
Karolinska Institutet
| 30 Jahre |
| C. Payne | M | 61 | 2 Jahre | |
| Andres McAllister | M | 68 | 7 Jahre | |
| Magnus Westgren | M | 73 |
Karolinska Institutet
| 18 Jahre |
| George Church | M | 69 |
Harvard Medical School
| 38 Jahre |
| Carola Elisabet Lemne | M | 66 |
Karolinska Institutet
| 26 Jahre |
| Ola Winqvist | M | 58 |
Karolinska Institutet
| - |
| Torgny H. Svensson | M | - |
Karolinska Institutet
| - |
| Erik Gustav Magnus Axelson | M | - |
Karolinska Institutet
| - |
| Lars Olov Larsson | M | - |
Karolinska Institutet
| - |
| Lennart Hammarstrom | M | - |
Karolinska Institutet
| - |
| John Wahren | M | - |
Karolinska Institutet
| - |
| Ralf Morgenstern | M | 72 |
Karolinska Institutet
| - |
| Christian Åbyholm | M | 52 | - | |
| Jan Peter Andersson | M | 73 |
Karolinska Institutet
| 14 Jahre |
| Marc Wiles | M | - | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Bradley Thompson | M | 67 | 17 Jahre | |
| Francesco Sinigaglia | M | 71 |
BioXell SpA
 BioXell SpA BiotechnologyHealth Technology BioXell SpA provides medical services. The company researches and develops drugs to treat urological, inflammatory, and related disorders. The company was founded in 2002 and is headquartered in Segrate, Italy. | 10 Jahre |
| Johan Rutger Christenson | M | 65 |
Aprea Therapeutics AB
Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | - |
| Barbara Anna Heller | F | 56 | 7 Jahre | |
| Jonathan Hepple | M | 53 |
Aprea Therapeutics AB
Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | 5 Jahre |
| Martin Gertsch | M | 59 | 15 Jahre | |
| Guido Magni | M | 70 |
Aprea Therapeutics AB
Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | 4 Jahre |
| Scott Coiante | M | 57 |
Aprea Therapeutics AB
Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | 4 Jahre |
| Michael Oredsson | M | 64 | 5 Jahre |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Schweden | 45 | 45,00% |
| Vereinigte Staaten | 22 | 22,00% |
| Kanada | 18 | 18,00% |
| Norwegen | 10 | 10,00% |
| Vereinigtes Königreich | 8 | 8,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Bernd Seizinger
- Persönliches Netzwerk
